Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter April 24, 2013

Effect of recombinant insulin-like growth factor-1 treatment on short-term linear growth in a child with Majewski osteodysplastic primordial dwarfism type II and hepatic insufficiency

  • Maria Felicia Faienza EMAIL logo , Angelo Acquafredda , Mariangela D’Aniello , Lucia Soldano , Flaviana Marzano , Annamaria Ventura and Luciano Cavallo

Abstract

We report the case of a boy affected by severe intrauterine and postnatal growth retardation, microcephaly, facial dysmorphisms and postnecrotic cirrhosis, diagnosed at birth as having Seckel syndrome, and subsequently confirmed as Majewski osteodysplastic primordial dwarfism type II (MOPD II) on the basis of clinical and radiological features of skeletal dysplasia. At our observation (6 years 7 months) he presented height –10.3 standard deviation score (SDS), weight –22.1 SDS, head circumference –8 SDS, delayed bone age of 4 years with respect to chronological age. In consideration of the low levels of insulin-like growth factor-1 (IGF-1) as well as of hepatic insufficiency, we started the treatment with recombinant human IGF-1 (rhIGF-1) at the dose of 0.04 mg/kg in 2 doses/day, with an increase of 0.04 mg/kg after 1 week until the maximum dose of 0.12 mg/kg. We observed an early response to rhIGF-1 treatment, with a shift of height velocity from 1.8 cm/year (–4.6 SDS) at 4 cm/year (–1.9 SDS), and an increase in bone age of 1.5 years during the first 6 months. rhIGF-1 treatment does not seem to be able to replace the physiological action of IGF-1 in patients with MOPD II and hepatic insufficiency, however, it seems to preserve the typical growth pattern of MOPD II patients, avoiding a further widening of the growth deficiency in these subjects.


Corresponding author: Maria Felicia Faienza, MD, Department of Biomedical Sciences and Human Oncology, University of Bari ‘A. Moro’, Piazza G. Cesare, 11, 70124, Bari, Italy, Phone: +39 805593075, Fax: +39 805592287

We would like to thank Valérie Cormier-Daire from Department of Genetics Hôpital Necker/Paris/FRANCE for the molecular genetic analysis.

Conflict of interest statement: The authors declare that they have no conflict of interest.

References

1. Hall JG, Flora C, Scott CI Jr, Pauli RM, Tanaka KI. Majewski osteodysplastic primordial dwarfism type II (MOPD II): Natural history and clinical findings. Am J Med Genet A 2004;130A: 55–72.10.1002/ajmg.a.30203Search in Google Scholar

2. Griffith E, Walker S, Martin CA, Vagnarelli P, Stiff T, et al. Mutations in pericentrin cause Seckel syndrome with defective ATR-dependent DNA damage signaling. Nat Genet 2008;40:232–6.10.1038/ng.2007.80Search in Google Scholar

3. Rauch A, Thiel CT, Schindler D, Wick U, Crow YJ, et al. Mutations in the pericentrin (PCNT) gene cause primordial dwarfism. Science 2008;319:816–9.10.1126/science.1151174Search in Google Scholar

4. Bober MB, Niiler T, Duker AL, Murray JE, Ketterer T, et al. Growth in individuals with Majewski osteodysplastic primordial dwarfism type II caused by pericentrin mutations. Am J Med Genet A 2012;158A:2719–25.10.1002/ajmg.a.35447Search in Google Scholar

5. Rauch A. The shortest of the short: Pericentrin mutations and beyond. Best Pract Res Clin Endocrinol Metab 2011;25:125–30.10.1016/j.beem.2010.10.015Search in Google Scholar

6. Majewski F, Ranke M, Schinzel A. Studies of microcephalic primordial dwarfism II: the osteodysplastic type II of primordial dwarfism. Am J Med Genet 1982;12:23–35.10.1002/ajmg.1320120104Search in Google Scholar

7. Huang-Doran I, Bicknell LS, Finucane FM, Rocha N, Porter KM, et al. Genetic defects in human pericentrin are associated with severe insulin resistance and diabetes. Diabetes 2011;60: 925–35.10.2337/db10-1334Search in Google Scholar

8. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res 2003;13:113–70.10.1016/S1096-6374(03)00038-8Search in Google Scholar

9. Conchillo M, de Knegt RJ, Payeras M, Quiroga J, Sangro B, et al. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol 2005;43:630–6.10.1016/j.jhep.2005.03.025Search in Google Scholar PubMed

10. Osio D, Dahlgren J, Wikland KA, Westphal O. Improved final height with long-term growth hormone treatment in Noonan syndrome. Acta Paediatr 2005;94:1232–7.10.1111/j.1651-2227.2005.tb02081.xSearch in Google Scholar PubMed

Received: 2012-12-10
Accepted: 2013-2-18
Published Online: 2013-04-24
Published in Print: 2013-08-01

©2013 by Walter de Gruyter Berlin Boston

Downloaded on 28.3.2024 from https://www.degruyter.com/document/doi/10.1515/jpem-2012-0397/html
Scroll to top button